| The incidence and management of infusion reactions to infliximab: a large center experience A Cheifetz, M Smedley, S Martin, M Reiter, G Leone, L Mayer, S Plevy Official journal of the American College of Gastroenterology| ACG 98 (6 …, 2003 | 622 | 2003 |
| Crohn disease: epidemiology, diagnosis, and management JD Feuerstein, AS Cheifetz Mayo Clinic Proceedings 92 (7), 1088-1103, 2017 | 586 | 2017 |
| The risk of retention of the capsule endoscope in patients with known or suspected Crohn's disease AS Cheifetz, AA Kornbluth, P Legnani, I Schmelkin, A Brown, S Lichtiger, ... Official journal of the American College of Gastroenterology| ACG 101 (10 …, 2006 | 462 | 2006 |
| Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis KS Nanda, AS Cheifetz, AC Moss Official journal of the American College of Gastroenterology| ACG 108 (1), 40-47, 2013 | 417 | 2013 |
| Ulcerative colitis: epidemiology, diagnosis, and management JD Feuerstein, AS Cheifetz Mayo Clinic Proceedings 89 (11), 1553-1563, 2014 | 367 | 2014 |
| Functional variants in the LRRK2 gene confer shared effects on risk for Crohn’s disease and Parkinson’s disease KY Hui, H Fernandez-Hernandez, J Hu, A Schaffner, N Pankratz, NY Hsu, ... Science translational medicine 10 (423), eaai7795, 2018 | 343 | 2018 |
| Interventions for prevention of post‐operative recurrence of Crohn's disease G Doherty, G Bennett, S Patil, A Cheifetz, AC Moss Cochrane Database of Systematic Reviews, 2009 | 292 | 2009 |
| Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases K Papamichael, AS Cheifetz, GY Melmed, PM Irving, NV Casteele, ... Clinical Gastroenterology and Hepatology 17 (9), 1655-1668. e3, 2019 | 279 | 2019 |
| Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease M Akbari, S Shah, FS Velayos, U Mahadevan, AS Cheifetz Inflammatory bowel diseases 19 (1), 15-22, 2013 | 279 | 2013 |
| Psoriasis associated with anti‐tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature G Cullen, D Kroshinsky, AS Cheifetz, JR Korzenik Alimentary pharmacology & therapeutics 34 (11‐12), 1318-1327, 2011 | 242 | 2011 |
| Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study BP Vaughn, M Martinez-Vazquez, VR Patwardhan, AC Moss, ... Inflammatory bowel diseases 20 (11), 1996-2003, 2014 | 240 | 2014 |
| Management of active Crohn disease AS Cheifetz Jama 309 (20), 2150-2158, 2013 | 230 | 2013 |
| Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab K Papamichael, KA Chachu, RK Vajravelu, BP Vaughn, J Ni, ... Clinical Gastroenterology and Hepatology 15 (10), 1580-1588. e3, 2017 | 220 | 2017 |
| Monoclonal antibodies, immunogenicity, and associated infusion reactions. A Cheifetz, L Mayer Mount Sinai Journal of Medicine 72 (4), 2005 | 214 | 2005 |
| The burden of inflammatory bowel disease: a patient-reported qualitative analysis and development of a conceptual model J Devlen, K Beusterien, L Yen, A Ahmed, AS Cheifetz, AC Moss Inflammatory bowel diseases 20 (3), 545-552, 2014 | 175 | 2014 |
| Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis S Hanauer, R Panaccione, S Danese, A Cheifetz, W Reinisch, ... Clinical Gastroenterology and Hepatology 17 (1), 139-147, 2019 | 173 | 2019 |
| Histology grade is independently associated with relapse risk in patients with ulcerative colitis in clinical remission: a prospective study T Zenlea, EU Yee, L Rosenberg, M Boyle, KS Nanda, JL Wolf, KR Falchuk, ... Official journal of the American College of Gastroenterology| ACG 111 (5 …, 2016 | 170 | 2016 |
| Capsule endoscopy retention: is it a complication? AS Cheifetz, BS Lewis Journal of clinical gastroenterology 40 (8), 688-691, 2006 | 169 | 2006 |
| Complementary and alternative medicines used by patients with inflammatory bowel diseases AS Cheifetz, R Gianotti, R Luber, PR Gibson Gastroenterology 152 (2), 415-429. e15, 2017 | 162 | 2017 |
| Histologic markers of inflammation in patients with ulcerative colitis in clinical remission L Rosenberg, KS Nanda, T Zenlea, A Gifford, GO Lawlor, KR Falchuk, ... Clinical Gastroenterology and Hepatology 11 (8), 991-996, 2013 | 135 | 2013 |
